iScience Interventional, a private device and imaging company in Menlo Park, California, have announced the execution of a clinical and commercial supply agreement with Johnson & Johnson Pharmaceutical Research & Development LLC. The agreement will govern the provision of iScience’s “iTrack 275” micro-catheter device for use by J&J’s Centocor division in its’ cell therapy trial, CNTO 2476, for the treatment of atrophic AMD. The micro-catheter device is inserted through a sclerotomy and choroidal fistula with a cannula to dispense a sodium hyaluronate solution creating a retinal bleb. An illuminated beacon at the tip of the micro-catheter allows visualization through the pupil facilitating delivery of umbilical derived cells.